Hyperhomocysteinemia and Venous Thrombosis

The International Journal of Lower Extremity Wounds

Volumn 1, Issue 1, 2002, Pages 4-12

  Lee, Paul ^a   Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

coagulation; folic acid; hyperhomocysteinemia; oxyradicals; venous thrombosis; vitamin B12

Indexed keywords

EID: 84993736248     PISSN: 15347346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153473460200100102     Document Type: Article

References (96)

1. Toborek M, Kopieczna-Grzebieniak E, Dródz M, et al. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis 1995; 115: 217-224.
2. Welch GW, Loscalzo J. Homocysteine and atherosclerosis. N Engl J Med 1998; 338: 1042-1050.
3. Ubbink JB. Homocysteine—an atherogenic and a thrombogenic factor? Nutr Rev 1995; 53: 323-325.
4. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocysteinuria due to cystathione β-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
5. den Heijer M, Kostor T, Blom HJ, et al. Homocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 334: 759-762.
6. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinaemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997; 11: 1157-1168.
7. Willems HP, den Heijer M, Bos GM. Homocysteine and venous thrombosis: outline of a vitamin intervention trial. Semin Thromb Hemost 2000; 26: 297-304.
8. Langman LJ, Ray JG, Evrovski J, et al. Hyperhomocyst(e)inemia and increased risk of venous thromboembolism: more evidence from case-control study. Arch Intern Med 2000; 160: 961-964.
9. D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
10. Ueland PM, Refsum H. Review article: plasma homocysteine, a risk factor for vascular disease, plasma levels in health, disease and drug therapy. J Lab Clin Med 1989; 114: 473-501.
11. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-1057.
12. Mayer EM, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-527.
13. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
14. Port SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
15. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530.
16. Griffin JH, Evatt BL, Zimmerman TS, et al. Deficiency of protein-c in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
17. Allaart CF, Poort SR, Rosendaal FR, et al. Increased risk of venous thrombosis in carriers of hereditary protein-c deficiency defect. Lancet 1993; 341: 134-138.
18. Zöller B, Berntsdottes A, Garcia de Fructos P, et al. Resistance to activated protein C as the additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
19. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms: the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-722.
20. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 3: 285-286.
21. Koster T, Blann AD, Briët E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-155.
22. Kraaijenhagen RA, Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
23. Ueland PM, Refsum H, Stabler SP, et al. Total homocysteine in plasma or serum. Methods and clinical application. Clin Chem 1993; 39: 1764-1779.
24. Kang S-S, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-462.
25. Kang S-S, Wong PWK, Cook HY, et al. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest 1986; 77: 1482-1486.
26. Kang S-S, Wong PWK, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-298.
27. Prasad K. Homocysteine, a risk factor for cardiovascular disease. Int J Angiol 1999; 8: 76-86.
28. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, et al, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 1279-1327.
29. Ballal RS, Jacobson DW, Robinson K. Homocysteine: update on a new risk factor. Cleveland Clin J Med 1997; 64: 543-549.
30. Kang S-S, Zhou J, Wong PWK, et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421.
31. Miller JW, Ribayamercado JD, Russell RM, et al. Effect of vitamin B6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55: 1154-1160.
32. Allen RH, Stabler SP, Savage DG, et al. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1994; 7: 1344-1353.
33. Selhub J, Jacques PF, Wilson PWF, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
34. Wight TN. Vessel proteoglycans and thrombogenesis. In: Spact TH, editor. Progress in hemostasis and thrombosis. New York: Grume & Stratton; 1980. p. 1-39.
35. Esmon CT, Owen WG. Identification of endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A 1981; 78: 2249-2252.
36. Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A 1977; 74: 3922-3926.
37. Loskuttoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A 1977; 74: 3903-3907.
38. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-1408.
39. Graeber JE, Slott JH, Ulane RE, et al. Effect of homocysteine and homocysteine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982; 16: 490-493.
40. Mudd SH, Levy HL. Disorders of transulfuration. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, et al, editors. The metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill; 1983. p. 522-559.
41. McDonald L, Bray C, Field C, et al. Homocystinuria, thrombosis, and the blood-platelets. Lancet 1964; 1: 745-746.
42. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-1916.
43. Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256: 1002-1007.
44. Ratnoff OD. Activation of Hageman factor by L-homocysteine. Science 1968; 162: 1007-1009.
45. Lenz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81: 683-689.
46. Kamphuisen PW, Eikenboom JCJ, Bertina RM. Elevated factor VIII levels and risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731-737.
47. Heinecke JW, Rosen H, Suzuki LA, et al. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103.
48. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993; 14: 683-693.
49. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
50. Welch GN, Upchurch GR, Keaney JF, et al. Homocyst(e)ine decreases cell redox potential in vascular smooth muscle cells. J Am Coll Cardiol 1996; 27(Suppl A):163A. Abstract.
51. Misra HP. Generation of superoxide free radical during auto-oxidation of thiols. J Biol Chem 1974; 249: 2151-2155.
52. Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett 1982; 138: 33-36.
53. Lang D, Kredan MB, Moat SJ, et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta. Arterioscler Thromb Vasc Biol 2000; 20: 422-427.
54. Polack B, Pernod G, Barro C, et al. Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis 1997; 27: 193-200.
55. Shatos MA, Doherty JM, Orfeo T, et al. Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals. J Biol Chem 1992; 267: 597-601.
56. Jourdan A, Aguejouf O, Imbault P, et al. Experimental thrombosis model induced by free radicals: application to aspirin and other different substances. Thromb Res 1995; 79: 109-123.
57. Hayashi T, Honda TG, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-2936.
58. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein c activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
59. Lenz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein-c activation by thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914.
60. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-1386.
61. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-2879.
62. Harker LA, Ross R, Slichter SJ, et al. Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
63. Wall RT, Harlan LM, Harker LA, et al. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-121.
64. Blundell G, Jones BG, Rose FA, et al. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996; 122: 163-172.
65. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worchester DVT Study. Arch Intern Med 1991; 151: 933-938.
66. Nordstrom M, Lindblad B, Bergquist D, et al. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
67. Lee JCL, Spittell JA, Sauer WG, et al. Hypercoagulability associated with chronic ulcerative colitis: changes in blood coagulation factors. Gastroenterol 1968; 54: 76-85.
68. Koster T, Rosendaal FR, Briet E, et al. Protein-c deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761.
69. Rosendaal FR, Koster T, Vandenbrouke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein-c resistance). Blood 1995; 85: 1504-1508.
70. Schimke RN, McKusick VA, Huang T, et al. Homocystinuria: studies of 20 families with 38 affected members. JAMA 1965; 193: 711-719.
71. Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962; 37: 505-513.
72. Gibson JB, Carson NAJ, Neill DW. Pathological findings in homocystinuria. J Clin Pathol 1964; 17: 427-437.
73. Bienvenu T, Ankri A, Chadefaux B, et al. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 1993; 70: 123-129.
74. Brattstrom L, Tengborn L, Lagerstedt C, et al. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57.
75. Falcon CR, Cattaneo M, Panzeri D, et al. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-1083.
76. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995; 15: 1321-1323.
77. Fermo I, Vigano’ D’Angelo S, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753.
78. den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-885.
79. Cattaneo M, Martinelli I, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 335: 974-975.
80. Simioni P, Prandoni P, Burlina A, et al. Hyperhomocysteinemia and deep vein thrombosis. Thromb Haemost 1996; 76: 883-886.
81. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-1782.
82. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-569.
83. Willems HPG, den Heijer M, Bos GMG. Homocysteine and venous thrombosis. Outline of a vitamin intervention trial. Semin Thromb Hemost 2000; 26: 297-304.
84. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1988; 80: 874-877.
85. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-2206.
86. Petri M, Roubenoff R, Dallol GE, Nadeau MR, Selhub J, Rosenburg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-1124.
87. Chauveau P, Chadefaux B, Conde M, et al. Long term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failures. Miner Electrolyte Metab 1996; 22: 106-109.
88. Abou-Gazala T, Lobo A, Alsous F, et al. High plasma homocysteine in patients with coronary artery disease can be reduced by folic acid supplementation. J Am Coll Cardiol 1997; 27(Suppl 2A):488A.
89. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolase reductase genotypes. Arterioscler Thromb Vasc Biol 1997; 17: 1157-1162.
90. Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995; 237: 381-388.
91. Ubbink JB, Vermaak WJ, Vander Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-1933.
92. Brattstrom LE, Israelsson B, Jeppsson JO, et al. Folic acid—an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215-221.
93. Homocysteine lowering trialists’ collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Br Med J 1998; 316: 894-898.
94. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338: 1009-1015.
95. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340: 1449-1454.
96. Mohr DN, Silverstein MD, Heit JD, et al. The venous stasis syndrome after deep vein thrombosis or pulmonary embolism: a population based study. Mayo Clin Proc 2000; 75: 1249-1256.